Trends in Hospitalizations Related to Invasive Aspergillosis and Mucormycosis in the United States, 2000–2013
Open accessThe DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Abstract
Background: Invasive aspergillosis (IA) and mucormycosis contribute to substantial mortality, especially among immunocompromised persons, including those with hematopoietic stem cell transplant (HSCT), hematologic malignancy (HM), and solid organ transplant (SOT). Methods: Using International Classification of Diseases, Ninth Revision codes available in the National Inpatient Sample, a hospital discharge database, we estimated IA-related hospitalizations (IA-RH), mucormycosis-RH (M-RH), HSCT-RH, HM-RH, and SOT-RH during 2000–2013. United States census data were used to calculate overall M-RH and IA-RH rates and present trends; estimated annual numbers of HSCT-RH, HM-RH, and SOT-RH served as denominators to calculate M-RH and IA-RH rates occurring with these conditions. Weighted least-squares technique was used to test for linear trends and calculate average annual percentage change (APC). Results: There were an estimated 169 110 IA-RH and 9966 M-RH during 2000–2013. Overall, IA-RH and M-RH rates per million persons rose from 32.8 to 46.0 (APC = +2.9; P < .001) and 1.7 to 3.4 (APC = +5.2%; P < .001), respectively, from 2000 to 2013. Among HSCT-RH, there was no significant change in M-RH rate, but a significant decline occurred in IA-RH rate (APC = −4.6%; P = .004). Among HM-RH, the rate of M-RH increased (APC = +7.0%; P < .001), but the IA-RH rate did not change significantly (APC = +1.2%; P = .073). Among SOT-RH, M-RH (APC = +6.3%; P = .038) and IA-RH rates (APC = +4.1%; P < .001) both increased. Conclusions: Overall IA-RH and M-RH rates increased during 2000–2013, with a doubling of M-RH. Mucormycosis-related hospitalization occurring in conjunction with certain comorbidities increased, whereas IA-RH rates among patients with the comorbidities, decreased, remained stable, or increased to a lesser extent than M-RH.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Freifeld, A. G., Bow, E. J., Sepkowitz, K. A., Boeckh, M. J., Ito, J. I., Mullen, C. A., Raad, I. I., Rolston, K. V., Young, J.-A. H., & Wingard, J. R. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir073 · Cited by 3,463
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044 · cited 2×
“Roden et al [35] observed a male to female rate ratio of 1.5.”
BackgroundInfluentialTomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J.-A. H., & Boeckh, M. A. (2009) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2009.06.019 · Cited by 1,797 · cited 1×
“Although fluconazole, with its proven survival benefit, remains the mainstay of antifungal prophylaxis for most patients with HM and HSCT, use of prophylaxis to prevent IA, in certain HM and HSCT patients during high-risk periods, is recommended [28].”
BackgroundPappas, P. G., Alexander, B. D., Andes, D. R., Hadley, S., Kauffman, C. A., Freifeld, A., Anaissie, E. J., Brumble, L. M., Herwaldt, L., Ito, J., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651262 · Cited by 1,570 · cited 3×
“Single-center studies subsequently conducted in the United States [8, 9] and studies of specific patient populations over relatively short periods [4, 6, 10] suggest a rise in the incidence of mucormycosis, and IA to a lesser extent.”
BackgroundKontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/651263 · Cited by 1,456 · cited 1×
“Single-center studies subsequently conducted in the United States [8, 9] and studies of specific patient populations over relatively short periods [4, 6, 10] suggest a rise in the incidence of mucormycosis, and IA to a lesser extent.”
BackgroundEpidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448 · cited 1×
“Single-center studies subsequently conducted in the United States [8, 9] and studies of specific patient populations over relatively short periods [4, 6, 10] suggest a rise in the incidence of mucormycosis, and IA to a lesser extent.”
BackgroundHealthcare Cost and Utilization Project (HCUP)
(2016) · The SAGE Encyclopedia of Pharmacology and Society · doi:10.4135/9781483349985.n182 · Cited by 1,035
Neofytos, D., Horn, D., Anaissie, E., Steinbach, W., Olyaei, A., Fishman, J., Pfaller, M., Chang, C., Webster, K., & Marr, K. (2009) · Clinical Infectious Diseases · doi:10.1086/595846 · Cited by 801
Skiada, A., Pagano, L., Groll, A., Zimmerli, S., Dupont, B., Lagrou, K., Lass-Florl, C., Bouza, E., Klimko, N., Gaustad, P., et al. (2011) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2010.03456.x · Cited by 748
Laboratory diagnosis of invasive aspergillosis
Hope, W., Walsh, T., & Denning, D. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70238-3 · Cited by 495 · cited 2×
“Improved diagnostics, especially with introduction of the galactomannan assay in the last decade, may have altered detection of IA and hence observed trends in IA [13].”
BackgroundResult
Research works printed but not linked: 1
- Park, 2011, Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006, Emerg Infect Dis, 17, 1855, 10.3201/eid1710.110087 · DOI · Paper page
Cited by
Estimation of Direct Healthcare Costs of Fungal Diseases in the United States
Benedict, K., Jackson, B. R., Chiller, T., & Beer, K. D. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy776 · Cited by 438
“This finding is particularly notable since mucormycosis rates doubled from 2000 to 2013 [23].”
BackgroundSelf-citationThe rapid emergence of antifungal-resistant human-pathogenic fungi
Lockhart, S. R., Chowdhary, A., & Gold, J. A. W. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00960-9 · Cited by 308
“It is the primary cause of invasive aspergillosis, an infection responsible for substantial morbidity (>14,000 annual US hospitalizations) and mortality (>1,200 annual US deaths) 82–84 and requiring treatment with systemic antifungal medications.”
BackgroundA New Age in Molecular Diagnostics for Invasive Fungal Disease: Are We Ready?
Kidd, S. E., Chen, S. C.-A., Meyer, W., & Halliday, C. L. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02903 · Cited by 166
“PCR Detection of Mucormycosis Invasive fungal diseases caused by Mucorales fungi are increasing, especially among immunocompromised patients and in those with poorly controlled diabetes mellitus (Vallabhaneni et al., 2017; Millon et al., 2019).”
BackgroundBurden of Candidemia in the United States, 2017
Tsay, S. V., Mu, Y., Williams, S., Epson, E., Nadle, J., Bamberg, W. M., Barter, D. M., Johnston, H. L., Farley, M. M., Harb, S., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa193 · Cited by 163
Self-citationToda, M., Beer, K. D., Kuivila, K. M., Chiller, T. M., & Jackson, B. R. (2021) · Environmental Health Perspectives · doi:10.1289/ehp7484 · Cited by 161
“Approximately 15,000 U.S. hospitalizations with invasive aspergillosis are estimated to occur annually based on medical coding data, with incidence increasing over the past decade in part because of the growing numbers of patients at risk (Benedict et al. 2019; Vallabhaneni et al. 2017).”
Metadata
- Authors
- Vallabhaneni, S., Benedict, K., Derado, G., & Mody, R. K.
- Affiliations
- Centers for Disease Control and Prevention (US)
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-01-01
- Volume
- 4
- Issue
- 1
- Pages
- ofw268-ofw268
- ISSN
- 2328-8957 (ISSN-L)
- PMC
- PMC5413990
- OpenAlex
- W2577939788
- Cited by
- 98
- References
- 37
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 7 · 2023: 13 · 2022: 10 · 2021: 15 · 2020: 11 · 2019: 14 · 2018: 8 · 2017: 1
- FWCI
- 7.16
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- Locations
- Open Forum Infectious Diseases (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- Centers for Disease Control and Prevention
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- invasive aspergillosis, mucormycosis, hospitalization trends, hematopoietic stem cell transplantation, hematologic malignancies, solid organ transplantation, immunocompromised patients, fungal infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.